Alberto Espay Presents Promising Interim Results of Phase III Parkinson’s Study

Share

Alberto Espay, MD, examines John, who had recently undergone surgery as part of the Phase III Levodopa-Carbidopa Intestinal Gel clinical trial at UC Health University Hospital. Photo by Cindy Starr / Mayfield Clinic

Alberto Espay, MD, Director of Clinical Research at the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders, on Thursday presented promising preliminary results of an ongoing, multi-site study of a continuous medication-delivery system for people with Parkinson’s disease. The delivery system is designed to reduce the severe on-again-off-again fluctuations that patients normally experience when taking levodopa orally, and at intervals, throughout the day.

Dr. Espay presented the early results from the 54-month, Phase III clinical trial of Abbott’s Levodopa-Carbidopa Intestinal Gel (LCIG) treatment system at the International Congress of Parkinson’s Disease and Movement Disorders in Toronto. Dr. Espay, an Assistant Professor of Neurology at UC, is a lead investigator in the clinical trial, whose study sites include the the UC Neuroscience Institute at University Hospital.

Patients participating in the study receive levodopa, which boosts dopamine in the brain, through a tube that leads directly into the duodenum, the first part of the small intestine. The medication is suspended as a stable gel from a cassette worn outside the body (photo below).

A news release from Abbott stated that patients reported improvement in motor symptoms after 12 weeks of treatment with the intestinal gel. They experienced a decrease in “off” time (a re-emergence of symptoms when medication is not working) and an increase in “on” time without dyskinesias, the involuntary movements associated with most treatments used to manage the disease.

“With advanced Parkinson’s disease, the goal of treatment is to provide patients with as much “on” time as possible, while limiting the troublesome dyskinesias they may experience,” Dr. Espay said in the news release. “The interim data from this study of LCIG show clinically meaningful improvements in these important measures.”

The interim report was based on data from 192 patients with advanced Parkinson’s disease who had completed 12 weeks of treatment with LCIG for 16 hours per day. Eleven of those 192 patients were treated by Dr. Espay’s team at the Gardner Center and University Hospital.

At 12 weeks, patients reported an average of 3.9 fewer hours of “off” time and 4.6 additional hours of “on” time without troublesome dyskinesias. Adverse events occurred in 168 patients (87.5 percent) and appeared to be largely related to the surgical procedure. Adverse events included abdominal pain (30.7 percent), complications of device insertion (21.4 percent) and procedural pain (17.7 percent).  The most severe complications from surgery were peritonitis (abdominal inflammation, 3.6 percent) and pneumoperitoneum (gas or air in the peritoneal cavity, 5.7 percent).  Fourteen patients (7.3 percent) withdrew because of an adverse event.

For more information about the Cincinnati portion of the study, please contact kristy.sullivan@uc.edu or call (513) 558-6517.

This entry was posted in UC Neuroscience Blog and tagged . Bookmark the permalink. Both comments and trackbacks are currently closed.
  • Print This Page
  • Make an Appointment: Schedule Now
  • UCNI Weekly Blog
  • Join Our Email List
    for Bi-Monthly Updates

    Click here to continue.
  • Hope Stories

    • Dick’s Story: Ischemic Stroke

      Dick's Story: Ischemic Stroke As a firefighter who attends regular EMS drills, Dick Koeniger was well versed in the signs and symptoms of stroke. While driving home with a friend one evening last June, he suddenly noticed that his peripheral vision was slightly impaired....
    • Blake’s Story: Medulloblastoma

      Blake's Story: Medulloblastoma Blake knew he was in the right hands the moment he saw the surgeon’s wrists. Dr. John M. Tew, Blake’s neurosurgeon, was wearing one of Lance Armstrong’s yellow LiveStrong cancer bracelets. So was Blake. Dr. Tew, who was also sporting...
    • Kevin’s Story: Acoustic Neuroma

      Kevin's Story: Acoustic Neuroma Kevin was in his mid-40s when he began to notice that he wasn’t hearing quite as well as in the past. But the change was gradual, so he didn’t worry about it. A few years went by, and the hearing...
    • John’s Story: Glioblastoma

      John's Story: GlioblastomaJohn, a retired painter and carpenter, is a tall, solidly built man with a strong inclination toward getting things done. A former Vista volunteer who was equally comfortable running a food co-op in an underserved neighborhood or standing near the...
    • Christine’s Story: Stroke

      Christine's Story: StrokeThere was a sliver of a chance, maybe, and most likely the emergency room doctor thought there was no chance at all. Christine had arrived at the community hospital comatose, brought by her parents, who had come home after working...
    • Charles Sabine’s Story: Huntington’s Disease

      Charles Sabine's Story: Huntington's DiseaseIn 2005 the NBC war correspondent Charles Sabine made the life-altering decision to face up to his family history of Huntington’s disease and undergo genetic testing. The odds, he knew, were 50-50 that he, too, had the gene and would...
    • Brian’s Story: Meningioma

      Brian's Story: Meningioma “Carefree” is the word Brian uses to describe his life back then. He was 39 years old, happily married and the father of three children under the age of 5. “Life was busy, but that felt normal,” he says, reflecting. “The only...
    • Tim’s Story: Traumatic Brain Injury

      Tim's Story: Traumatic Brain Injury This story includes a graphic description of Tim’s traumatic brain injury. If you are squeamish or faint of heart, you may wish to close this file and turn to a different story of hope.   Tim was outdoors doing what he liked...
    • Janis’s Story: Parkinson’s Disease

      Janis's Story: Parkinson's Disease When Janis Yelton gratefully enrolled in a ground-breaking study at the University of Cincinnati Neuroscience Institute, one of four institutes of the UC College of Medicine and UC Health, she was wracked by pain from advanced Parkinson’s disease, taking 32...
    • John’s Story: Epilepsy

      John's Story: Epilepsy In golf they call it a “bad lie.” A golfer strikes the ball, hoping to place it in a comfortable location on the fairway or the green, but the ball winds up somewhere else entirely – on the side of a...